Cwm LLC Grows Stake in Edwards Lifesciences Corporation $EW

Cwm LLC lifted its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 24.1% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 40,851 shares of the medical research company’s stock after purchasing an additional 7,935 shares during the period. Cwm LLC’s holdings in Edwards Lifesciences were worth $3,195,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of EW. Brighton Jones LLC purchased a new stake in shares of Edwards Lifesciences during the fourth quarter worth about $266,000. Wealth Enhancement Advisory Services LLC increased its stake in shares of Edwards Lifesciences by 13.5% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 77,016 shares of the medical research company’s stock worth $5,582,000 after purchasing an additional 9,188 shares in the last quarter. State of Alaska Department of Revenue increased its stake in shares of Edwards Lifesciences by 2.7% during the first quarter. State of Alaska Department of Revenue now owns 69,069 shares of the medical research company’s stock worth $5,006,000 after purchasing an additional 1,827 shares in the last quarter. Global X Japan Co. Ltd. increased its stake in shares of Edwards Lifesciences by 116.1% during the first quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company’s stock worth $29,000 after purchasing an additional 216 shares in the last quarter. Finally, ORG Wealth Partners LLC purchased a new stake in Edwards Lifesciences during the 1st quarter valued at about $38,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

Edwards Lifesciences stock opened at $74.50 on Friday. The firm has a 50 day simple moving average of $77.54 and a 200-day simple moving average of $76.16. Edwards Lifesciences Corporation has a 1-year low of $64.89 and a 1-year high of $83.00. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. The stock has a market cap of $43.74 billion, a price-to-earnings ratio of 10.72, a price-to-earnings-growth ratio of 3.49 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.05. The business had revenue of $1.53 billion during the quarter, compared to analysts’ expectations of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The business’s revenue for the quarter was up 11.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have commented on EW shares. William Blair upgraded shares of Edwards Lifesciences to a “strong-buy” rating in a report on Friday, July 25th. BTIG Research upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and set a $100.00 price objective for the company in a report on Tuesday, July 29th. JPMorgan Chase & Co. increased their price objective on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the company a “neutral” rating in a report on Friday, July 25th. Robert W. Baird increased their price objective on shares of Edwards Lifesciences from $78.00 to $79.00 and gave the company a “neutral” rating in a report on Friday, July 25th. Finally, Morgan Stanley increased their price objective on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the company an “equal weight” rating in a report on Tuesday, July 15th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $87.06.

Insider Buying and Selling

In related news, insider Larry L. Wood sold 8,950 shares of the stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the transaction, the insider owned 206,900 shares of the company’s stock, valued at approximately $16,150,614. This trade represents a 4.15% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Daniel J. Lippis sold 4,114 shares of the stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the transaction, the vice president directly owned 22,002 shares of the company’s stock, valued at $1,748,278.92. The trade was a 15.75% decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.